Costs for screening, intervention and hospital treatment generated by the Malmö Preventive Project: a large‐scale community screening programme

Abstract. Norinder A, Persson U, Nilsson P, Nilsson J‐Å, Hedblad B, Berglund G (Swedish Institute for Health Economics, Lund; and University Hospital, Malmö, Sweden). Costs for screening, intervention and hospital treatment generated by the Malmö Preventive Project: a large‐scale community screening programme. J Intern Med 2002; 251: 44–52.

[1]  A. Eggen,et al.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? , 1991, BMJ.

[2]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[3]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[4]  K. Eriksson,et al.  Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project , 1996, Journal of internal medicine.

[5]  P. Puska,et al.  Cost-effectiveness of the North Karelia Hypertension Program 1972-1977 , 1986, Medical care.

[6]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[7]  K. Eriksson,et al.  Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity , 2000, Journal of internal medicine.

[8]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[9]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[10]  A. Fletcher.  Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. , 1991, Journal of hypertension.

[11]  J. McMurray,et al.  The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin , 1997, BMJ.

[12]  W. Hollingworth,et al.  Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population , 1996, BMJ.

[13]  B. Lindgren,et al.  The cost-effectiveness of a new antihypertensive drug, doxazosin , 1989 .

[14]  A. Haycox,et al.  Clinical guidelines—the hidden costs , 1999, British medical journal.

[15]  L Lindholm,et al.  Alcohol advice in primary health care--is it a wise use of resources? , 1998, Health policy.

[16]  H Wedel,et al.  Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.

[17]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[18]  J. McMurray.  The health economics of the treatment of hyperlipidemia and hypertension. , 1999, American journal of hypertension.

[19]  E. Trell.  Community-based preventive medical department for individual risk factor assessment and intervention in an urban population. , 1983, Preventive medicine.

[20]  L. Borgquist,et al.  The cost effectiveness of lipid lowering in Swedish primary health care , 1996, Journal of internal medicine.

[21]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[22]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[23]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[24]  B. Jönsson,et al.  The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial , 1999, Diabetologia.